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2′,7′-Dichlorodihydroﬂuorescein diacetateproduction of reactive oxygen species (ROS) by Complex I in isolated open
bovine heart submitochondrial membrane fragments during forward electron transfer in presence of
NADH, by means of the probe 2′,7′-Dichlorodihydroﬂuorescein diacetate. ROS production by Complex I is
strictly related to its inhibited state. Our results indicate that different Complex I inhibitors can be grouped
into two classes: Class A inhibitors (Rotenone, Piericidin A and Rolliniastatin 1 and 2) increase ROS
production; Class B inhibitors (Stigmatellin, Mucidin, Capsaicin and Coenzyme Q2) prevent ROS production
also in the presence of Class A inhibitors. Addition of the hydrophilic Coenzyme Q1 as an electron acceptor
potentiates the effect of Rotenone-like inhibitors in increasing ROS production, but has no effect in the
presence of Stigmatellin-like inhibitors; the effect is not shared by more hydrophobic quinones such as
decyl-ubiquinone. This behaviour relates the prooxidant CoQ1 activity to a hydrophilic electron escape site.
Moreover the two classes of Complex I inhibitors have an opposite effect on the increase of NADH–DCIP
reduction induced by short chain quinones: only Class B inhibitors allow this increase, indicating the
presence of a Rotenone-sensitive but Stigmatellin-insensitive semiquinone species in the active site of the
enzyme. The presence of this semiquinone was also suggested by preliminary EPR data. The results
suggest that electron transfer from the iron–sulphur clusters (N2) to Coenzyme Q occurs in two steps
gated by two different conformations, the former being sensitive to Rotenone and the latter to
Stigmatellin.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Complex I is a very large enzyme catalyzing at the entry point of
the mitochondrial electron transport chain [1–3]. The total number of
subunits in the bovine heart enzyme is 45 [4] for a molecular mass of
about 1000 KDa. Seven subunits are products of the mitochondrial
genome [5,6] that correspond to hydrophobic subunits named ND1–
ND6 and ND4 L. The molecular mechanism of catalysis of this enzyme
is not completely understood. The main reason is the lack of detailed
structural information of the membrane part of Complex I, althoughein diacetate; NADH, β-Nicoti-
pecies; MTT, 3-[4,5-dimethyl-
Flavin mononucleotide; BHM,
ine; DOC, Deoxycholate; SMP,
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ll rights reserved.X-ray structure of the extramembrane part was determined recently
by Sazanov and Hinchliffe [7] utilizing Thermus thermophilus HB-8
enzyme. The minimal active form of Complex I is that found in
bacteria, composed of 14 subunits, all of which are homologous to
their mitochondrial counterparts. Based on this comparison, all other
subunits are called “accessory subunits” and their functional role in
the mitochondrial enzyme is not yet clear. The Complex I enzyme
oxidizes NADH transferring electrons to a lipid soluble electron carrier,
namely Ubiquinone or Coenzyme Q (CoQ). Based on the thermo-
dynamic proﬁles of redox active groups, the FMN is considered to be
the direct electron acceptor of NADH and subsequently electrons are
transferred to the iron–sulphur clusters. Bovine heart Complex I
contains 8 distinct iron–sulphur clusters (cluster N1a, N3, N1b, N4, N5,
N6a, N6b, N2). Clusters N3–N6 are considered to share the same
midpoint redox potential (Em) values (−250 mV), and are called the
isopotential group. Two clusters have different characteristics: N1a,
that is the [2Fe–2S] type cluster, and has the lowestmidpoint potential
(Em=−370 mV) and cluster N2, that is the [4Fe–4S] type cluster
which has the highest Em value (between −150 mV and −50 mV),
and is located close to the interface between the peripheral and the
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electron donor to ubiquinone. In the tightly coupled bovine heart
SMP, initially three distinct EPR semiquinone (SQ) signals were
proposed as Complex I components [8], but subsequently revised to
two species of SQ signals [9]; one is uncoupler sensitive the other is
insensitive. In the presence of reduced cluster N2, the former SQ
species shows extremely fast spin relaxation (thus designated as
SQNf) while the latter shows much slower spin relaxation (designated
as SQNs). Direct spin–spin interaction between cluster N2 and SQNf
was demonstrated and their mutual distance was estimated to be
12 Å [10,11]. In uncoupled SMP only the slowly relaxing SQ species is
observed [8,9].
Complex I is inhibited by more than 60 different families of
compounds [12] starting from Rotenone, the prototype of this series,
to a number of synthetic insecticides/acaricides. These inhibitors
were grouped into three classes based on their effects on the kinetic
behaviour of the enzyme: Class I/A (the prototype of which is
Piericidin A), Class II/B (the prototype of which is Rotenone) and
Class C (the prototype of which is Capsaicin). Nevertheless, from
kinetic studies it has not been possible to assign different binding
sites for these three classes of inhibitors. Thus it is commonly
accepted that they share the same large hydrophobic pocket in the
enzyme [13].
Complex I is also involved in the formation of the trans-membrane
proton gradient with a stoichiometry of 4H+/2e−. The limited
knowledge about the 3D-structure and the function of the whole
Complex I makes it difﬁcult to predict the proton pumpingmechanism
of Complex I across the inner mitochondrial membrane [9,14].
Besides its well known redox role in the electron transport chain,
Complex I is also considered to be one of the main sites of reactive
oxygen species (ROS) production; electrons leaked at Complex I can
reduce oxygen and give rise to superoxide anion [15]. The mechanism
of superoxide production by Complex I is not yet clear probably
because of the lack of knowledge on the exact sequence of the electron
carriers and how electron transfer is coupled to proton translocation.
The sites of ROS production in the mitochondrial electron transport
chain have been localized in Complex I and Complex III [16]. Whereas
the site of electron escape in Complex III has been identiﬁed in the so
called center “o”, the direct oxygen reductant site in Complex I has not
been established yet.
Recently, using different Complex I inhibitors to functionally
dissect the enzyme, it was suggested that iron–sulphur cluster N2
could be the site of the electron leak [17], but N2–SQNf region [18],
ubisemiquinone (SQNf) [19], FMN [15,20,21] and iron–sulphur cluster
N1a [22] have also been proposed as electron donors to oxygen. In
addition, it was found that defective Complex I produces more
reactive oxygen species (ROS) [16], suggesting that structural modi-
ﬁcations of the enzyme may play a crucial role in the ROS production
process.
The superoxide production by Complex I is much higher during the
reverse electron transport from succinate to NAD+ [19,23], than
during the forward electron transport. The reasons of this discrepancy
are still not understood.
An understanding of the detailed mechanism of reaction of
Complex I is required not only for advancement in basic knowledge
but also in biomedical research. In fact, a number of devastating
neurodegenerative disorders are associatedwith Complex I deﬁciency,
resulting in a decline of energy production by the respiratory chain
and in increased production of reactive oxygen species (ROS) (for
reviews see [24–28]).
Based upon the latter observations we have studied the effect of
different Complex I inhibitors on the ROS production to elucidate the
mechanism by which Complex I transfers electrons to molecular
oxygen, with the additional aim to exploit superoxide generation to
shed light on the mechanism of electron transfer to the natural
acceptor, Coenzyme Q10.2. Materials and methods
2.1. Materials
2′,7′-Dichlorodihydroﬂuorescein diacetate (DCFDA) was purchased
fromMolecular probes, Invitrogen, Milano Italy. Mucidin (Strobilurin A)
was a kind gift from Dr. F. Nerud of the Academy of Sciences in Prague,
Czech Republic. Rolliniastatin-1 and -2 were gifts from Dr E. Estornell of
the University of Valencia, Spain. Piericidin A and Stigmatellin were
purchased from Fluka, Sigma-Aldrich, Milano, Italy. All other chemicals
were purchased from Sigma-Aldrich, Milano, Italy.
2.2. Preparations
Submitochondrial particles (SMP) were prepared from bovine
heart mitochondria (BHM) by sonic irradiation of the frozen and
thawed BHM [29]; the particles were essentially broken membrane
fragments [30]. Proteinwas evaluated by the Biuret method of Gornall
et al. [31] with addition of 10% sodium deoxycholate and using bovine
serum albumin (BSA) as the standard.
2.2.1. Measure of hydrogen peroxide production
The method used to measure H2O2 production in submitochon-
drial particles (SMP) is based on the ﬂuorogenic probe 2′,7′-
Dichlorodihydroﬂuorescein diacetate (DCFDA or H2DCFDA) which
emits an intense green ﬂuorescence only after deacylation and
subsequent oxidation [32,33]. The advantage to use this probe is
that it does not inhibit the activity of Complex I [34]. Alternatively
H2O2 productionwas measured using Amplex Red. ROS production by
SMP was measured in a ﬂuorescence plate reader using a 96-well
microtiter plate. In eachwell were present 0.5mg/ml SMP (pretreated
with 1.8 μMMucidin) and 5 μMDCFDA or 10 μM Amplex Red to a ﬁnal
volume of 0.2 ml with KCl, 10 mM TRIS, 1 mM EDTA buffer, pH 7.5,
25 °C. The reaction was started by the addition of 150 μM NADH, in
presence and in absence of different respiratory inhibitors and/or
quinone acceptors.
2.2.2. Enzyme assays
NADH–CoQ reductase was assayed essentially as described by Yagi
[35] and modiﬁed by Degli Esposti et al. [36] in the presence of 2 mM
KCN and 2 μM Antimycin A to block Complexes IV and III, respectively.
Determination of the kinetic constants was accomplished at saturat-
ing concentration of NADH (150 μM) and 150 μM of CoQ1 following
the decrease in absorbance at 340 minus 380 nm, in a Jasco V550
spectrophotometer equipped with dual wavelength device, using an
extinction coefﬁcient of 3.5 mM−1 cm−1.
NADH–O2 reductase activity was assayed essentially in the same
conditions avoiding only KCN and Antimycin A in the assaymixture. To
compare the inhibition effect of different Complex I inhibitors with
ROS production, we performed the NADH–CoQ1 reductase assays with
high protein concentration (0.25 mg/ml of SMP).
NADH–DCIP reductase activity was assayed as above, following the
reduction of DCIP absorbance at 748 nm using an extinction
coefﬁcient of 0.8 mM−1 cm−1 with 40 μg/ml of SMP. Activity was
recorded in the presence and absence of Complex I inhibitors and
CoQ1 (25 μM) or DB (25 μM).
2.2.3. EPR sample preparation
EPR samples were prepared as follows. Submitochondrial particles
were suspended in the reaction buffer (Sucrose 0.25 M, TRIS 10 mM,
EDTA 1 mM) to be 30 mg/mL. The suspension in a glass test tube was
kept on ice. Antimycin A 5 μM, Carboxin 100 μM and Mucidin 1.8 μM
were added and the mixtures were incubated on ice for at least 5 min.
SMP samples were treated with different Complex I inhibitors to
completely block the enzyme: 10 μM Rotenone and 80 μM Stigma-
tellin. The reaction was initiated by adding 150 μM NADH.
Fig. 2. ROS production in SMP (0.5 mg/ml) treated with 1.8 μM Mucidin, 10 μM DPI,
75 μM CoQ1, 1 μM Rotenone, 1 μM Rotenone plus 75 μM CoQ1 and 1 μM Rotenone plus
50 μM DB. ROS production was detected following the ﬂuorescence variations in
presence of 5 μM DCFDA. Each value was detected after 2400 s from 150 μM NADH
addition and is expressed as percent of ﬂuorescence change with respect to the control.
Data are the mean of at least four different determinations.
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immediately frozen in dry ice/ethanol mixture, typically within 10 s
after adding the substrate and were stored in liquid nitrogen until
analysis.
2.2.4. EPR measurements
EPR experiments were performed at the Department of Chemical
Sciences, University of Padova, Italy, with a Bruker ER 200D spectro-
meter operating at X-band (9.4 GHz), equipped with a rectangular
cavity ER4102ST, and a variable-temperature controller Bruker ER 4111
VT; the microwave frequency was measured by a frequency counter
(model HP 5342A).
All spectra were obtained using the following parameters:
microwave power 0.66 mW; modulation amplitude 0.5 mT; modula-
tion frequency 100 kHz; time constant 41 ms; conversion time 82 ms;
scan width 10 mT; 1024 points; temperature 180 K; sample volume
300 μl. All spectra have an average of 9 scans and have been corrected
by subtraction of the oxidized SMP background.
3. Results
3.1. Suitability of ﬂuorescent probes to investigate ROS production in SMP
Fluorescent probes are widely used for ROS detection in biological
systems; at present several such probes are available: dihydro-
compounds such as 2′,7′-Dichlorodihydroﬂuorescein diacetate
(DCFH–DA), dihydroethidium (HE) and 10-acetyl-3,7-dihydroxyphe-
noxazine (AmplexRed) are mostly used. DCFH and Amplex Red are
suggested as speciﬁc probes for H2O2, while dihydroethidium seems
to be more suitable for O2
U− detection. Anyway all ﬂuorescent probes
for ROS detection suffer a lack of selectivity and it is generally thought
that they react with various types of ROS [22,23,27], although they are
generally used for detecting total oxidative activity in living cells or
tissues.
DCFDA is routinely used in intact cells, being taken up and
deacetylated by endogenous hydrolases to a form (DCFH) that is then
oxidized by peroxides (including H2O2) to ﬂuorescent 2′,7′-Dichloro-
ﬂuorescein (DCF). It has been shown [34] that mitochondria and sub-
mitochondrial particles can deacetylate the probe and oxidize it by ROS.Fig. 1. Suitability of DCFDA probe (5 μM) for H2O2 determination in presence of SMP
(0.5 mg/ml) supplemented with 150 μMNADH (CTRL) and treated with 1 μMRotenone
(Rotenone). The amount of the deacetylated probe by SMP is largely exceeding that one
oxidized by respiratory substrates as indicated by high ﬂuorescence achieved with 5 μM
of H2O2. Fluorescence intensity was detected after 2400 s from NADH addition. No
ﬂuorescence was detected by addition of 5 μM hydrogen peroxide in absence of SMP.
Data are the mean of at least ﬁve different determinations±standard deviation.Using DCFDA or Amplex Red for reliable superoxide detection in
SMP, it is required that deacetylation of DCFDA probe and conversion
of superoxide to hydrogen peroxide proceed at a rate that is not rate-
limiting with respect to superoxide production.
Fig. 1 shows that addition of hydrogen peroxide enhances the
probe ﬂuorescence to an extent largely exceeding that one obtained
with respiratory substrates, suggesting that the non-reactive acetyl
ester is cleaved at a rate higher than that of natural H2O2 production.
Considering DCFH more speciﬁc for peroxide than for superoxide
we have evaluated the effect of SOD on the ﬂuorescence levels
detected. The conversion of superoxide anion to hydrogen peroxide
catalyzed by SOD induces a modest ﬂuorescence increase both in
control and in Complex I inhibited particles (i.e. +30% in presence of
Rotenone plus SOD vs Rotenone alone, data not shown) without
substantial alterations of their relative ratio. This feature suggests that
our system is suitable for ROS detection even in the absence of SOD.
Amplex Red is a non-ﬂuorescent molecule that originates
resoruﬁn, a highly ﬂuorescent product when oxidized by H2O2
[37,38]. As an advantage over DCFH, Amplex Red presents low
background ﬂuorescence as well as stability and high ﬂuorescence
power on oxidation. Furthermore, its excitation and emission
maximum wavelengths subsist in a spectral zone that has little
susceptibility to interference from autoﬂuorescence in assays where
biological samples are used [37,38].
Amplex Red is normally used in associationwith HRP (horse radish
peroxidase). In our system, oxidation of the probe is achieved even
without HRP addition.
Addition of KCN completely prevents Amplex Red oxidation
suggesting that in mitochondrial membranes are present enzymes
with KCN sensitive peroxidase activity. In fact cyanide has beenwidely
used as an inhibitor of many peroxidases and oxidases [39].
Nevertheless, it must be taken into account that in biological
systems NADH may interfere with Amplex Red/peroxidase assay
system resulting in a decreased ﬂuorescence [40].
Dihydroethidium has been used as a ﬂuorescent probe for
detecting O2
U− [41–44]. Indeed, when HE is oxidized by superoxide,
it originates ethidium (E+), a ﬂuorescent compound [45].
Even this probe shows some limitations: cytochrome c is able to
oxidize HE and the superoxide detection might not be quantitative by
this method because HE increases the superoxide/hydrogen peroxide
dismutation rate [42,46].
In addition E+ ﬂuorescence is enhanced in presence of DNA. For
this reason HE is not suitable for our DNA-free system.
Because of the different limitations showed by these probes we
have carried out experiments using all three probes, with super-
imposable results. Nevertheless, the systematic studies reported were
performed mainly using DCFDA.
Table 1
Effect of different Complex I inhibitors on ROS production in SMP supplemented with
150 μM NADH
Inhibitor DCFDA Amplex Red
Rotenone (2 μM) +53%±23 +62%±3
Piericidin A (1 μM) +101%±30 +53%±5
Rolliniastatin 1 (30 μM) +17%±4
Rolliniastatin 2 (30 μM) +17%±9
Stigmatellin (60 μM) −11%±5 −34%±3
Mucidin (80 μM) −7%±6 −8%±3
Capsaicin (50 μM) −49%±3
CoQ2 (20 μM) −39%±23
The results are expressed as percent of ﬂuorescence variationwith respect to the control
treated with 1.8 μM Mucidin. Fluorescence intensity was collected after 2400 s from
NADH addition. Each value is the mean of at least 10 different determinations.
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substrates
To study ROS production by Complex I in situ, we have used
mitochondrial membrane fragments (SMP) derived by ultrasonicFig. 3. Panel A: Representative experiment of ROS detection in SMP (0.5mg/ml) inhibitedwit
were treated with 1.8 μMMucidin (to block electron transfer and to avoid ROS production by
concentration (1.5 mg/ml) and Mucidin concentration: 5.4 μM. Inserts show the full time cirradiation of Bovine Heart Mitochondria (BHM). SMP used in this
study have been shown to be broken membrane fragments devoid of
permeability barriers and of membrane potential [30]. For this reason
they are not coupled and are incapable of reverse electron transfer
from succinate to NAD+. Since the latter reaction is considered to be a
major source of ROS, these particles represent an ideal system to
investigate direct electron transfer in Complex I from NADH to CoQ
without interference by the reverse reaction.
Mucidin is an inhibitor of Complex III at center “o” (or P) that
completely prevents ROS formation by this complex [17] even in
presence of Antimycin A.
Addition of NADH to SMP inhibited with 1.8 μM Mucidin, that
completely inhibits electron transfer in Complex III, does not induce
electron escape from Complex I tomolecular oxygen, suggesting that a
fully reduced state of Complex I is necessary but not sufﬁcient for ROS
production.
For this reason Mucidin can functionally isolate Complex I from
further segments of the respiratory chain and we used 1.8 μM
Mucidin-treated SMP as control in all experiments.
Addition of oxidized CoenzymeQ1, or decylubiquinone (DB) to such
Mucidin-inhibited particles is not able to stimulate ROS production.h Class A (i.e. 2 μMRotenone) and Class B (i.e. 60 μMStigmatellin) inhibitors. All samples
Complex III) and supplemented with 150 μMNADH. Panel B: As panel A except for SMP
ourse of the experiments.
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strong increase in ROS generation. Moreover addition of CoQ1 to the
Rotenone-inhibited enzyme stimulates ROSproduction,while addition
of decylubiquinone has no effect or even induces a slight decrease of
ROS production (Fig. 2). Because both CoQ1 and DB are good oxidizing
substrates for Complex I activity, this difference is very puzzling and
needs an explanation. The reason for this different behaviour may be
due to the higher water solubility of CoQ1 with respect to DB [47],
suggesting that the prooxidant activity of oxidized quinones is due to
their interaction with an hydrophilic site for electron escape.
3.2.1. Effect of Complex I inhibitors on ROS production
Complex I activity is very sensitive to a large spectra of compounds
(cf. [12] for a review), among which we can ﬁnd short chain quinones
(i.e. CoQ2) and Complex III center “o” inhibitors (i.e. Stigmatellin). For
this reason we have undertaken a deep analysis on the effect of
different Complex I inhibitors on ROS production. The results depicted
in Table 1 and Fig. 3 allow a distinction of inhibitors into two classes:
Piericidin A and Rolliniastatin-1 and -2 behave like Rotenone, whereas
Stigmatellin, Capsaicin, Mucidin and Coenzyme Q2 (CoQ2) prevent the
oxidation of the probe and rather decrease it below control levels. The
effect of an inhibitor of the former class to stimulate ROS production is
abolished by the combined presence of an inhibitor of the latter class.
Analyzing the compounds listed in these two classes we can
observe that the distinction between ROS-inducing and ROS-
preventing inhibitors resembles the classic Complex I inhibitors
distinction based on their antagonistic effect with respect to quinone
or quinol.
The response of the probe to the ROS detection is not linear and is
weak in the ﬁrst 15 min using 0.5 mg/ml protein as described in
Materials andMethods (Fig. 3A). For this reasonwe have chosen a timeFig. 4. Correlation between percentage of DCFDA ﬂuorescence variation and percentage of
Correlation between ROS production and Complex I inhibition by Rotenone. Panel B) Correl
prepared as follows: SMPwere incubatedwith increasing amounts of Rotenone or Piericidin A
of increasing amounts of Stigmatellin on ROS produced by 100% Rotenone inhibited Comp
Piericidin A inhibited Complex I. Samples were prepared as follows: SMP completely inhi
Stigmatellin and ROS production was detected. The percentage of inhibition of NADH–CoQ
experiment. Each value is the mean of at least ten different determinations.of 40 min as standard time for our measurements. In parallel
experiments (Fig. 3B), using higher amount of protein (1.5 mg/ml),
we show that the ratio between inhibited and control samples is
retained both at 10 and at 40 min, suggesting that the ﬂuorescence
increase is representative of the amountof ROSproduced in our system.
ROS production is a typical chain reaction, described by a non
linear ﬂuorescence increase of the probes. This behaviour does not
allow a quantitative measure of ROS production rate, however the
ﬂuorescence value depends on the total amount of ROS produced and
remains proportional throughout the time course of the experiment.
Complex I activity can be also affected by compounds acting on the
FMN site such as DPI and pHMB (para-hydroxymercuribenzoate).
Both these inhibitors block the electron input to the redox centers
inside Complex I, also preventing electron delivery to molecular
oxygen. Moreover, addition of CoQ1 to a SMP sample inhibited by DPI
in presence of NADH has no effect on ROS production, suggesting that
the site involved in the CoQ1 prooxidant effect is located downstream
the DPI inhibition site (data not shown).
The ability of Complex I to produce ROS is strictly related to the
percent of inhibition exerted by Rotenone-like inhibitors as well as the
decrease of ROS generation by Stigmatellin is strictly related to the
extent of Stigmatellin inhibition of NADH–CoQ1 reductase activity
(Fig. 4A, B, C, D).
Inspection of panels A and B shows that Class A inhibitors
Rotenone and Piericidin A at concentrations inducing low extents of
inhibition fail to induce ROS generation; moreover, Rotenone and
Piericidin A exhibit a different behaviour, with a much more
pronounced lag in presence of the latter inhibitor.
Some experimental factors like low probe sensitivity or NADH
interference with the ﬂuorescent probe may partially explain the lack
of ROS production in presence of low inhibition levels.NADH–CoQ1 activity inhibition in presence of different Complex I inhibitors: Panel A)
ation between ROS production and Complex I inhibition by Piericidin A. Samples were
. For each samplewemeasured NADH:CoQ1 activity and ROS production. Panel C) Effect
lex I. Panel D) Effect of increasing amount of Stigmatellin on ROS produced by 100%
bited with 2 μM of Rotenone or Piericidin A were treated with increasing amounts of
1 activity exerted by the same amounts of Stigmatellin was determined in a parallel
Fig. 6. NADH–DCIP reductase activity related to the physiological quinone reducing site.
Data were obtained subtracting the DPI insensitive activity from the total DCIP
reductase activity. The stimulation effect of 20 μMDB on NADH–DCIP reductase activity
is maintained in presence of Stigmatellin but is abolished by Rotenone. Each value is the
mean of at least 5 different determinations. ⁎ pb0.005.
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have detected a lower DCF ﬂuorescence intensity in presence of NADH
150 μM.
Nevertheless Piericidin A requires a higher extent of Complex I
inhibition to start ROS production in comparison with Rotenone (60–
70% for Piericidin A vs 20–30% for Rotenone).
This behaviour may be due to the presence of two different
partially overlapping binding sites for Piericidin A, one with high
afﬁnity and the other with low afﬁnity and shared by Rotenone [48].
Piericidin A at low concentration is able to block electron transfer
without inducing ROS formation, whereas at high concentration it
behaves like Rotenone, both blocking electron transfer and inducing
ROS production.
In this scenario Piericidin A needs to occupy the Rotenone binding
site to trigger ROS production. Moreover titration of ROS production
induced by Rotenone in SMP partially pre-inhibited with Piericidin A
shows loss of the lag phase, suggesting an additive effect between
these two inhibitors (Fig. 5).
The overlapping between different inhibition sites inside Complex I
is also consistentwith the inhibition of ROS production observedwhen
Stigmatellin is added in presence of either Rotenone or Piericidin A.
(Fig. 4C, D). In the ﬁrst case we observe a linear correlation (Fig. 4C)
between Complex I inhibition and decrease of ROS production, in the
second case this correlation follows a sigmoidal behaviour (Fig. 4D)
suggesting that Piericidin A binding sites may partially overlap with
both Rotenone and Stigmatellin binding sites. Evidences about the
different effects onROSproduction and electron transport in Complex I
related to different sites of inhibition for acetogenin derivatives were
recently described by Miyoshi and coworkers [61].
3.3. Kinetic analysis of Complex I inhibitors on electron transfer to DCIP
DCIP is a hydrophilic electron acceptorwidely used to test Complex
I reductase activity; only 20–30% of this activity is sensitive to
Rotenone, while the remaining is both Rotenone and DPI insensitive.
This suggests the presence of at least two sites for DCIP reduction: one
independent of the DPI inhibition site, the second corresponding to
the physiological ubiquinone reducing site.
Short chain ubiquinone analogues like CoQ1 and DB increase
NADH–DCIP reductase activity in a Rotenone sensitive way, whereas
they do not increase activity in presence of DPI.
The stimulation of NADH–DCIP reductase activity by CoQ1 or DB
offers a new tool to investigate the electron transfer mechanism inside
the active site.
The two classes of Complex I inhibitors affect the stimulation of
DCIP reduction by short chain quinones in a different way. The results
listed in Fig. 6 show that Rotenone-like inhibitors prevent this
stimulation, while Stigmatellin-like inhibitors allow it.Fig. 5. Correlation between ROS production (indicated as percentage of DCFDA
ﬂuorescence variation) and percentage of NADH–CoQ1 inhibition by Rotenone in SMP
pretreated with 20 pmol/mg of Piericidin A. Addition of 20 pmol/mg of Piericidin A to
SMP results in 30% of inhibition of NADH–CoQ1 activity without triggering massive ROS
production.Since both classes of inhibitors prevent the reduction of quinones
to quinols, the extra DCIP reduction in presence of CoQ1 or DB might
be due to the presence of an intermediate species between the fully
oxidized and the fully reduced one: thus it must be the semiquinone
form of CoQ1 or DB generated inside the active site of Complex I. The
new ﬁnding resulting from this observation allows us to hypothesize
the presence of a semiquinone in the enzyme active site insensitive to
the Stigmatellin-like inhibitors. To test this hypothesis we started to
study semiquinone EPR spectra in SMP treated with Rotenone-like or
Stigmatellin-like inhibitors.
3.4. Preliminary semiquinone EPR data
It is known from the literature that Rotenone and Piericidin A
strongly reduce the semiquinone EPR signal intensity from Complex I
[8], while there are no data on the effect of Stigmatellin and
Stigmatellin-like inhibitors. We recorded EPR spectra of uncoupled
SMP treated with Rotenone, Stigmatellin, or both. Results are reported
in Fig. 7: our spectra show a Rotenone-sensitive signal centered at
g=2.005, identifying it as a semiquinone radical [11]. The spectra
conﬁrm a strong signal reduction in the presence of Rotenone while
the signal intensity is only slightly reduced in samples treated with
Stigmatellin (Fig. 7, left); in the presence of both inhibitors, the signal
intensity is equal to that detected when only Stigmatellin is present
(Fig. 7, right).
4. Discussion
Complex I is the most debated enzyme of the mitochondrial
respiratory chain, due to its high structural complexity and many
redox centers involved in the electron transfer from NADH to
ubiquinone. From the analysis of the midpoint redox potentials of
the enzyme prosthetic groups, FMN is the entry point of electrons
from NADH, while N2 iron–sulphur center is considered to be the
direct electron donor to endogenous ubiquinone.
A large number of compounds inhibit Complex I: Rotenone, as well
as other classic Complex I inhibitors (Piericidin A, Rolliniastatin-1 and
-2, Capsaicin, etc.), block electron transfer from iron–sulphur clusters
to the ubiquinone pool. Despite the different chemical structure of
Complex I inhibitors it has not been possible to identify different
binding sites in the enzyme, and it is commonly accepted that these
Fig. 7. EPR signals of the semiquinone radical in Complex I at 180 K. The systems contained 30 mg/ml of SMP in 300 μl, 150 μM CoQ1. The ubisemiquinone formation was initiated by
the addition of 150 μM NADH. Spectra were obtained at a microwave frequency of 9.4121 GHz, obtaining a value of g=2.005 for the semiquinone radical.
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overlapping binding sites [13].
We have exploited the ability of Complex I to transfer electrons
directly to molecular oxygen with the aim of elucidating not only the
site of electron escape but also the electron transfer pathway. The
results depicted in this work allow us to divide Complex I inhibitors
into two distinct classes depending on their effect on ROS production:
1. Class A inhibitors: inducing strong increase in ROS production.
2. Class B inhibitors: preventing ROS production.
Class A inhibitors include Rotenone, Piericidin A, Rolliniastatin-1
and -2, while Class B includes Stigmatellin, Capsaicin, Mucidin and
Coenzyme Q2.
Most of Class B compounds are also classical Complex III inhibitors,
acting at the so called center “o”, where they block electron transfer
from ubiquinol to the Rieske iron–sulphur protein, while CoQ2 is
known to be a poor electron acceptor from Complex I, on which it
exerts an inhibitory effect ascribed to the quinol form [47].
Class A inhibitors are thought to prevent access of physiological
CoQ10 to its reduction site [49], allowing the release of one electron to
molecular oxygen. On the other hand, Class B inhibitors appear to
directly prevent oxygen reduction presumably acting on the electron
escape site [12].
This behaviour raises the question of the identiﬁcation of the direct
reductant of molecular oxygen.
One of the possible candidates is the ubisemiquinone species [19];
EPR data reported by the Ohnishi group [8] showed that Complex I
inhibitors such as Rotenone and Piericidin A turn off the EPR signals
from semiquinone species.
From our results on the ROS production it appears that inhibitors
shutting down the semiquinone signals are also most efﬁcient in the
direct transfer of electrons to molecular oxygen. These results would
suggest that the endogenous semiquinone formed during the redox
cycle of the enzyme is not involved in ROS production. This conclusion
is in line with a previous report showing that in CoQ-depleted
mitochondria, Complex I is able to produce oxygen radicals at a rate
comparable with the enzyme in non-extracted mitochondria [17].
A secondmajor candidate as the electron donor to oxygen has been
proposed to be FMN [15,20,21]; recently Brandt and his coworkers
showed that ROS production was still present in a mutant Complex I
from Yarrowia lipolytica lacking iron–sulphur cluster N2, concluding a
direct involvement of FMN in this activity [50]. On the other handOhnishi and coworkers showed that DPI inhibits ROS production in
the forward electron transfer, while enhanced it in the reverse
electron transfer [18]. The loss of ROS detection in the presence of DPI
seems to exclude any involvement of FMN in favor of a direct
involvement of iron–sulphur clusters. In fact DPI inhibits the reduction
of iron–sulphur clusters while the reduced state of protein-bound
FMN is stabilized [51]. The FMN involvement in ROS production
remains an open question and the discrepancy found in literature
should be ascribed to the difﬁculty encountered in achieving a
complete inhibition in the NADH–O2 activity, moreover the NAD+/
NADH ratio seems to be crucial for electron escape from FMN [52].
Nevertheless the results reported in this work allow us to
distinguish Complex I inhibitors, both acting downstream the FMN
moiety, in two classes with opposite effect on ROS production. For this
reason it is reasonable to conclude that FMN is not directly involved in
electron escape to oxygen in our experimental conditions of forward
electron transfer in intact membranes. Previous investigations
demonstrating FMN as the electron donor to oxygen in forward
electron transfer were mainly performed in isolated Complex I or
subfragments thereof; a recent study by Ohnishi et al. [53] showed
that ROS were generated at the FMN site in isolated Complex I only in
absence of CoQ acceptors.
Another major candidate as direct oxygen reductant is the iron–
sulphur cluster N2 because of its highest midpoint potential. The
electron transfer from NADH to the ubiquinone in Complex I requires
the presence of at least eight iron–sulphur clusters, seven of which are
well protected from reacting with oxygenwith the exception of the N2
center. From structural and functional studies the iron–sulphur cluster
N2 seems to be localized in a region that should be accessible to
protein bound ubisemiquinone, to H+ ions and to water, hence this
region should be also accessible to molecular oxygen [54,55]. More-
over the mid point potential of cluster N2 is around−0.15 to−0.05 V
[56] and therefore it is compatible with the reduction of oxygen to
superoxide anion (mid point potential for the couple superoxide/
oxygen is −0.14 V) [57,58].
We favor the hypothesis indicating the cluster N2 as the direct
reductant of the molecular oxygen. To allow electron escape from
Complex I to oxygen the reduced state of the enzyme is not sufﬁcient,
as indicated by the lack of ROS production in the presence of 1.8 μM
Mucidin. In this condition and in the presence of saturating
concentration of NADH, Complex III is completely inhibited while
Complex I is fully reduced [59]. ROS production by Complex I requires
the presence of a Class A inhibitor besides the reduced state of the
Fig. 8. Proposed two step mechanism for electron transfer from NADH to quinone in
Complex I (A), in presence of Class A inhibitors (B) and in presence of Class B inhibitors
(C). The role of hydrophilic (CoQ1) and hydrophobic (DB) quinones is highlighted. CoQ1
can react with the physiological ubiquinone reducing site and, because of its higherwater
solubility, it can also reactwith the electronescape site, increasing superoxide production.
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(80 μM) we achieve full inhibition of both NADH–CoQ1 activity and
ROS production even in presence of Class A inhibitors.
It might be guessed that Class A inhibitors induce an enzyme
conformational change, making the electron escape site more
accessible to molecular oxygen, whereas Class B inhibitors would
either directly block this site, or make it less accessible by way of a
conformational change.
In this scenario the different behaviour of Coenzyme Q1 can be
explained referring to its higher water solubility with respect to the
physiological CoQ10 or the more hydrophobic analogue Decyl-
ubiquinone. It may be postulated that CoQ1, when added to a non-
inhibited enzyme, is transformed to the antioxidant quinol form in the
physiological quinone reducing site, thus explaining its lack of
promotion of ROS generation. However, in the presence of a Class A
inhibitor, CoQ1 cannot reach the physiological Q-binding site. In this
condition the enzyme is completely reduced and CoQ1 can react with a
hydrophilic site located upstream the physiological one. This reaction
results in a thermodynamically unstable CoQ1 semiquinone radical,
able to readily react with molecular oxygen in the presence of protons
[60].This behaviour would explain the prooxidant role of CoQ1, not
shared by other more hydrophobic analogues such as DB.
CoQ1 and DB increase NADH–DCIP reductase activity in a way
sensitive to Class A inhibitors, suggesting that this effect is mediated
by the physiological site. On the other hand this increased activity is
insensitive to Class B inhibitors. Since both classes of inhibitors
completely prevent quinol formation, the increase of NADH–DCIP
activity observed even in the presence of Class B inhibitors must be
ascribed to the presence of a semiquinone form in the active site.
Preliminary results obtained by EPR analysis of submitochondrial
particles treated with Class A and Class B inhibitors conﬁrm the
decrease of the semiquinone signal in presence of Class A inhibitors
but clearly show the presence of semiquinone in samples treated with
Class B inhibitors either alone or in presence of Class A inhibitors. This
behaviour is completely in line with the results obtained with DCIP.
5. Conclusions
The results of this investigation allow us to draw conclusions on
the mechanism of electron transfer from the iron–sulphur clusters to
ubiquinone. It is generally believed that center N2 is the direct
electron donor to CoQ10 in a two steps mechanism by which two
electrons are consecutively delivered to quinone to achieve its fully
reduced form. This hypothesis is supported by recent ﬁndings
published by Sazanov and coworkers, describing a linear disposition
for Fe–S clusters inside Complex I [7]. In a simple linear scheme
considering N2 center as the only direct electron donor to quinone,
our results suggest that Class B inhibitors would act upstream, while
Class A inhibitors would block electron ﬂow downstream N2 center.
However, this scheme is incompatible with a series of observations.
1) Class B inhibitors, normally considered quinol antagonists, cannot
act upstream the quinone reducing site [12].
2) Class B inhibitors, while blocking quinol formation, do not prevent
semiquinone formation (our observations).
To explain our results we would need a mechanism of bifurcated
electron transfer, in which an iron–sulphur cluster located upstream
N2 center would act as a “switch” for electron delivery in such a way
that one-electron quinone reduction to semiquinone and semiqui-
none reduction to quinol would be accomplished by two different
electron donors. Since it is highly unlikely that quinone can reach
iron–sulphur clusters other than N2, that is the only center not deeply
buried in the protein, the delivery of both electrons by N2 requires
that the switch between the two gated states is represented by a
suitable conformational change.The presence of oxidized CoQ10 in the Q-pocket induces an enzyme
conformation, allowing electron delivery to reduce CoQ10 to semi-
quinone. The semiquinone formation induces a conformational
change now allowing the delivery of the second electron to the
semiquinone to produce the fully reduced form. This mechanism is
schematically represented in Fig. 8A.
Class A inhibitors (Fig. 8B), not allowing access of the quinone to
the active site, would block the enzyme in a conformation that does
not allow quinone reduction but only permits electron delivery from
N2 to oxygen; on the other hand, Class B inhibitors (Fig. 8C) would
block the enzyme in a conformation allowing the ﬁrst electron
delivery to form the semiquinone, but the incapability to further
reduction to quinol; such conformation would not allow reaction of
N2 with oxygen.
This working hypothesis requires further experiments and EPR
characterization of the redox state of all prosthetic groups in the
enzyme to clarify the mechanism of quinone reduction by Complex I.
Acknowledgements
This work was supported by MIUR-Rome (Italy).
Dr. Christian Bergamini was supported by Marco Polo Fellowship
for a stage in Tomoko Ohnishi's laboratory from June to September
2007.
392 R. Fato et al. / Biochimica et Biophysica Acta 1787 (2009) 384–392References
[1] A. Matsuno-Yagi, T. Yagi, Introduction: Complex I—an L-shaped black box, J.
Bioenerg. Biomembr. 33 (2001) 155–157.
[2] M. Saraste, Oxidative phosphorylation at the ﬁn de siecle, Science 283 (1999)
1488–1493.
[3] B.E. Schultz, S.I. Chan, Structures and proton-pumping strategies of mitochondrial
respiratory enzymes, Annu. Rev. Biophys. Biomol. Struct. 30 (2001) 23–65.
[4] J. Carroll, I.M. Fearnley, R.J. Shannon, J. Hirst, J.E. Walker, Analysis of the subunit
composition of Complex I from bovine heart mitochondria, Mol. Cell Proteomics. 2
(2003) 117–126.
[5] A. Chomyn, M.W. Cleeter, C.I. Ragan, M. Riley, R.F. Doolittle, G. Attardi, URF6, last
unidentiﬁed reading frame of human mtDNA, codes for an NADH dehydrogenase
subunit, Science 234 (1986) 614–618.
[6] A. Chomyn, P. Mariottini, M.W. Cleeter, C.I. Ragan, A. Matsuno-Yagi, Y. Hateﬁ, R.F.
Doolittle, G. Attardi, Six unidentiﬁed reading frames of humanmitochondrial DNA
encode components of the respiratory-chain NADH dehydrogenase, Nature 314
(1985) 592–597.
[7] L.A. Sazanov, P. Hinchliffe, Structure of the hydrophilic domain of respiratory
Complex I from Thermus thermophilus, Science 311 (2006) 1430–1436.
[8] S. Magnitsky, L. Toulokhonova, T. Yano, V.D. Sled, C. Hagerhall, V.G. Grivennikova,
D.S. Burbaev, A.D. Vinogradov, T. Ohnishi, EPR characterization of ubisemiqui-
nones and iron–sulfur cluster N2, central components of the energy coupling in
the NADH–ubiquinone oxidoreductase (Complex I) in situ, J. Bioenerg. Biomembr.
34 (2002) 193–208.
[9] T. Ohnishi, J.E. Johnson Jr., T. Yano, R. Lobrutto, W.R. Widger, Thermodynamic and
EPR studies of slowly relaxing ubisemiquinone species in the isolated bovine heart
Complex I, FEBS Lett. 579 (2005) 500–506.
[10] T. Yano, W.R. Dunham, T. Ohnishi, Characterization of the delta muH+-sensitive
ubisemiquinone species (SQ(Nf)) and the interactionwith clusterN2: new insight into
theenergy-coupledelectron transfer inComplex I, Biochemistry. 44(2005)1744–1754.
[11] T. Ohnishi, J.C. Salerno, Conformation-driven and semiquinone-gated proton-
pump mechanism in the NADH–ubiquinone oxidoreductase (Complex I), FEBS
Lett. 579 (2005) 4555–4561.
[12] M. Degli Esposti, Inhibitors of NADH–ubiquinone reductase: an overview,
Biochim. Biophys. Acta. 1364 (1998) 222–235.
[13] J.G. Okun, P. Lummen, U. Brandt, Three classes of inhibitors share a common
binding domain in mitochondrial Complex I (NADH:ubiquinone oxidoreductase),
J. Biol. Chem. 274 (1999) 2625–2630.
[14] U. Brandt, Energy converting NADH:quinone oxidoreductase (Complex I), Annu.
Rev. Biochem. 75 (2006) 69–92.
[15] L. Kussmaul, J. Hirst, The mechanism of superoxide production by NADH:
ubiquinone oxidoreductase (Complex I) from bovine heart mitochondria, Proc.
Natl. Acad. Sci. U. S. A. 103 (2006) 7607–7612.
[16] S. Raha, B.H. Robinson, Mitochondria, oxygen free radicals, disease and ageing,
Trends Biochem. Sci. 25 (2000) 502–508.
[17] M.L. Genova, B. Ventura, G. Giuliano, C. Bovina, G. Formiggini, G. Parenti Castelli, G.
Lenaz, The site of production of superoxide radical in mitochondrial Complex I is
not a bound ubisemiquinone but presumably iron–sulfur cluster N2, FEBS Lett.
505 (2001) 364–368.
[18] S.T. Ohnishi, T. Ohnishi, S. Muranaka, H. Fujita, H. Kimura, K. Uemura, K. Yoshida, K.
Utsumi, A possible site of superoxide generation in the Complex I segment of rat
heart mitochondria, J. Bioenerg. Biomembr. 37 (2005) 1–15.
[19] A.J. Lambert, M.D. Brand, Inhibitors of the quinone-binding site allow rapid
superoxide production from mitochondrial NADH:ubiquinone oxidoreductase
(Complex I), J. Biol. Chem. 279 (2004) 39414–39420.
[20] Y. Liu, G. Fiskum, D. Schubert, Generation of reactive oxygen species by the
mitochondrial electron transport chain, J. Neurochem. 80 (2002) 780–787.
[21] A.D. Vinogradov, Catalytic properties of the mitochondrial NADH–ubiquinone
oxidoreductase (Complex I) and the pseudo-reversible active/inactive enzyme
transition, Biochim. Biophys. Acta. 1364 (1998) 169–185.
[22] Y. Kushnareva, A.N. Murphy, A. Andreyev, Complex I-mediated reactive oxygen
species generation: modulation by cytochrome c and NAD(P)+ oxidation–
reduction state, Biochem. J. 368 (2002) 545–553.
[23] A.J. Lambert, M.D. Brand, Superoxide production by NADH:ubiquinone oxidor-
eductase (Complex I) depends on the pH gradient across the mitochondrial inner
membrane, Biochem. J. 382 (2004) 511–517.
[24] S.M. Bailey, A. Landar, V. Darley-Usmar, Mitochondrial proteomics in free radical
research, Free. Radic. Biol. Med. 38 (2005) 175–188.
[25] S. DiMauro, M. Hirano, Mitochondrial encephalomyopathies: an update, Neuro-
muscul. Disord. 15 (2005) 276–286.
[26] S. Kerscher, N. Kashani-Poor, K. Zwicker, V. Zickermann, U. Brandt, Exploring the
catalytic core of Complex I by Yarrowia lipolytica yeast genetics, J. Bioenerg.
Biomembr. 33 (2001) 187–196.
[27] T. Yagi, B.B. Seo, S. Di Bernardo, E. Nakamaru-Ogiso, M.C. Kao, A. Matsuno-Yagi,
NADH dehydrogenases: from basic science to biomedicine, J. Bioenerg. Biomembr.
33 (2001) 233–242.
[28] M. Zeviani, S. Di Donato, Mitochondrial disorders, Brain 127 (2004) 2153–2172.
[29] R.E. Beyer, The isolation, Propertier, and Assay of ATP Synthetase II, Methods in
Enzymol. 10 (1967) 519–522.
[30] R. Fato, M. Cavazzoni, C. Castelluccio, G. Parenti Castelli, G. Palmer, M. Degli Esposti, G.
Lenaz, Steady-state kinetics of ubiquinol–cytochrome c reductase in bovine heart
submitochondrial particles: diffusional effects, Biochem. J. 290 (Pt.1) (1993)225–236.
[31] A.G. Gornall, C.J. Bardawill, M.M. David, Determination of serum proteins by
means of the Biuret reaction, J. Biol. Chem. 177 (1949) 751–766.[32] M.J. Black, R.B. Brandt, Spectroﬂuorometric analysis of hydrogen peroxide, Anal.
Biochem. 58 (1974) 246–254.
[33] C. Garcia-Ruiz, A. Colell, M. Mari, A. Morales, J.C. Fernandez-Checa, Direct effect of
ceramide on the mitochondrial electron transport chain leads to generation of
reactive oxygen species. Role of mitochondrial glutathione, J. Biol. Chem. 272
(1997) 11369–11377.
[34] M. Degli Esposti, Measuring mitochondrial reactive oxygen species, Methods 26
(2002) 335–340.
[35] T. Yagi, Inhibition by capsaicin of NADH–quinone oxidoreductases is correlated
with the presence of energy-coupling site 1 in various organisms, Arch. Biochem.
Biophys. 281 (1990) 305–311.
[36] M. Degli Esposti, A. Ghelli, M. Crimi, E. Estornell, R. Fato, G. Lenaz, Complex I and
Complex III of mitochondria have common inhibitors acting as ubiquinone
antagonists, Biochem. Biophys. Res. Commun. 190 (1993) 1090–1096.
[37] J.G. Mohanty, J.S. Jaffe, E.S. Schulman, D.G. Raible, A highly sensitive ﬂuorescent
micro-assay of H2O2 release from activated human leukocytes using a
dihydroxyphenoxazine derivative, J. Immunol. Methods 202 (1997) 133–141.
[38] M. Zhou, Z. Diwu, N. Panchuk-Voloshina, R.P. Haugland, A stable nonﬂuorescent
derivative of resoruﬁn for the ﬂuorometric determination of trace hydrogen
peroxide: applications in detecting the activity of phagocyte NADPH oxidase and
other oxidases, Anal. Biochem 253 (1997) 162–168.
[39] L.P. Solomonson, In: B. Vennesland, E.E. Conn, C.J. Knowles, J. Westley, I. Wissing
(Eds.), Cyanide in Biology, Academic Press, New York, 1981.
[40] A. Gomes, E. Fernandes, J.L. Lima, Fluorescence probes used for detection of
reactive oxygen species, J. Biochem. Biophys. Methods 65 (2005) 45–80.
[41] M.A. Barbacanne, J.P. Souchard, B. Darblade, J.P. Iliou, F. Nepveu, B. Pipy, F. Bayard,
J.F. Arnal, Detection of superoxide anion released extracellularly by endothelial
cells using cytochrome c reduction, ESR, ﬂuorescence and lucigenin-enhanced
chemiluminescence techniques, Free Radic. Biol. Med. 29 (2000) 388–396.
[42] L. Benov, L. Sztejnberg, I. Fridovich, Critical evaluation of the use of hydroethidine
as a measure of superoxide anion radical, Free Radic. Biol. Med. 25 (1998)
826–831.
[43] V.P. Bindokas, J. Jordan, C.C. Lee, R.J. Miller, Superoxide production in rat
hippocampal neurons: selective imaging with hydroethidine, J. Neurosci. 16
(1996) 1324–1336.
[44] S. Walrand, S. Valeix, C. Rodriguez, P. Ligot, J. Chassagne, M.P. Vasson, Flow
cytometry study of polymorphonuclear neutrophil oxidative burst: a comparison
of three ﬂuorescent probes, Clin. Chim. Acta. 331 (2003) 103–110.
[45] T. Munzel, I.B. Afanas, ev, A.L. Kleschyov, D.G. Harrison, Detection of superoxide in
vascular tissue, Arterioscler. Thromb. Vasc. Biol. 22 (2002) 1761–1768.
[46] M.M. Tarpey, D.A. Wink, M.B. Grisham, Methods for detection of reactive
metabolites of oxygen and nitrogen: in vitro and in vivo considerations, Am. J.
Physiol. Regul. Integr. Comp. Physiol. 286 (2004) R431–R444.
[47] R. Fato, E. Estornell, S. Di Bernardo, F. Pallotti, G. Parenti Castelli, G. Lenaz, Steady-
state kinetics of the reduction of coenzyme Q analogs by Complex I (NADH:
ubiquinone oxidoreductase) in bovine heart mitochondria and submitochondrial
particles, Biochemistry 35 (1996) 2705–2716.
[48] M. Gutman, T.P. Singer, J.E. Casida, Studies on the respiratory chain-linked reduced
nicotinamide adenine dinucleotide dehydrogenase. XVII. Reaction sites of
piericidin A and Rotenone, J. Biol. Chem. 245 (1970) 1992–1997.
[49] T. Friedrich, T. Ohnishi, E. Forche, B. Kunze, R. Jansen, W. Trowitzsch, G. Hoﬂe, H.
Reichenbach, H. Weiss, Two binding sites for naturally occurring inhibitors in
mitochondrial and bacterial NADH:ubiquinone oxidoreductase (Complex I),
Biochem. Soc. Trans. 22 (1994) 226–230.
[50] A. Galkin, U. Brandt, Superoxide radical formation by pure Complex I (NADH:
ubiquinone oxidoreductase) from Yarrowia lipolytica, J. Biol. Chem. 280 (2005)
30129–30135.
[51] A. Majander, M. Finel, M. Wikstrom, Diphenyleneiodonium inhibits reduction of
iron–sulfur clusters in the mitochondrial NADH–ubiquinone oxidoreductase
(Complex I), J. Biol. Chem. 269 (1994) 21037–21042.
[52] C.D. Barker, T. Reda, J. Hirst, The ﬂavoprotein subcomplex of Complex I (NADH:
ubiquinone oxidoreductase) from bovine heart mitochondria: insights into the
mechanisms of NADH oxidation and NAD+ reduction from protein ﬁlm
voltammetry, Biochemistry 46 (2007) 3454–3464.
[53] S.T. Ohnishi, K. Shinzawa-Itoh, S. Yoshikawa, T. Ohnishi, In: R.K. Porter, G. Davey
(Eds.), 15th European Bioenergetics Conference, Dublin, 2008, p. S36.
[54] A. Garofano, K. Zwicker, S. Kerscher, P. Okun, U. Brandt, Two aspartic acid residues
in the PSST-homologous NUKM subunit of Complex I from Yarrowia lipolytica are
essential for catalytic activity, J. Biol. Chem. 278 (2003) 42435–42440.
[55] L. Grgic, K. Zwicker, N. Kashani-Poor, S. Kerscher, U. Brandt, Functional signiﬁcance
of conserved histidines and arginines in the 49-kDa subunit of mitochondrial
Complex I, J. Biol. Chem. 279 (2004) 21193–21199.
[56] T. Ohnishi, Iron–sulfur clusters/semiquinones in Complex I, Biochim. Biophys.
Acta 1364 (1998) 186–206.
[57] F. Muller, The nature and mechanism of superoxide production by the electron
transport chain: its relevance to aging, J. Am. Aging Assoc. 23 (2000) 227–253.
[58] J. Petlicki, and T. G.M. vandeVen, J. Chem. Soc. FaradayTrans. 94 (1998) 2763–2767.
[59] A. Kroger, M. Klingenberg, Further evidence for the pool function of ubiquinone as
derived from the inhibition of the electron transport by Antimycin, Eur. J. Biochem.
39 (1973) 313–323.
[60] H. Nohl, L. Gille, K. Schonheit, Y. Liu, Conditions allowing redox-cycling
ubisemiquinone in mitochondria to establish a direct redox couple with
molecular oxygen, Free Radic. Biol. Med. 20 (1996) 207–213.
[61] M. Murai, N. Ichimaru, M.A. Abe, T. Nishioka, H. Miyoshi, Mode of inhibitory action
of Δlac-Acetogenins, a new class of inhibitors of bovine heart mitochondrial
Complex I, Biochemistry 45 (2006) 9778–9787.
